---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018798"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:06:04.401696+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track

## Summary
- Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.
- R&D expenses fell to $3.0M from $3.9M, driven by clinical-stage transitions.
- Cash at March 31, 2024: $21.8M, down from $26.4M; working capital $22.1M.
- Topline SAD results for oral CDI-988 (pan-coronavirus/norovirus) expected Q2 2024.
- Phase 2a influenza A study of CC-42344 enrollment complete; topline due H2 2024.

## SEC filing metadata
- accession: 0001493152-24-018798
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/0001493152-24-018798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018798
- JSON: https://secwatch.observer/filing/0001493152-24-018798.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018798.txt

## Key facts
- Earnings Releases
  Cocrystal Pharma, Inc. reported financial results for Q1 2024.
  - Period: Q1 2024
  - Result: reported results
  source text: Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/0001493152-24-018798-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.